Wiggin and Dana LLP One City Place 185 Asylum Street Hartford, Connecticut 06103-3402 860.297.3700 860.525.9380 fax www.wiggin.com

RECEIVED CENTRAL FAX CENTER

SEP 1 1 2007

WIGGIN AND DANA

This message is intended for the use

of the individual or entity to which it is addressed and may contain

information that is privileged, con-

fidential and exempt from disclo-

sure. If the reader of this message is

not the intended recipient or an

employee or agent responsible for

delivering the message to the intended recipient, you are hereby notified that any dissemination, dis-

tribution or copying of this message is strictly prohibited. If you have

received this communication in error please notify us immediately

by telephone and return the original message to us by mail. Thank you.

Counsellors at Law

Telefax Transmittal

Date:

September 11, 2007

To / Company / Telefax:

USPTO - Commissioner for Patents

571-273-8300

From:

Todd E. Garabedian, Ph.D.

Telephone / Email:

860.297-3716 / tgarabedian@wiggin.com

Client / matter code:

185160 / 10

Please copy:

We will copy:

Special Instructions

In re Application of: Mats Hellström et al. Docket No.: 0208/76419-PCT-US/RDK

Application No. :

: 10/581,761

Filec.

: June 5, 2006 .

Our Reference: 102959-202

Assignee

: AngioGenetics Sweden AB

Title: ANGIOGENESIS AFFECTING POLYPEPTIDES, PROTEINS, AND

COMPOSITION, AND METHODS OF USE THEREOF

Enclosed are:

(1) Transmittal Letter (1 page); and

(2) Revocation of original power of attorney and grant of new power of

attorney and change of correspondence address (3 pages).

\185[6\10\55239.1

4 page(s) following this page

SEP 1 1 2007 PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	MATS HELLSTRÖM ELISABET WALLGARD MATTIAS KALÉN	Docket:	0208/76419-PCT-US/RDK	
Serial No.:	10/581,761	Art Unit:		
Filed:	June 5, 2006	Examiner:		
Assignee:	AngioGenetics Sweden AB	Conf. No.:		
Customer No.:	27267	Our Reference	102959-202	
Title:	ANGIOGENESIS AFFEC COMPOSITION, AND MI	TING POLYPEPTIDES, P ETHODS OF USE THERE	ROTEINS, AND OF	
Commissioner for Par P.O. Box 1450 Alexandria, VA 22313				
TRANSMITTAL LETTER				
application: 1. REVOCAT	ase find the following do Tion of Power of Atto E of Correspondence (b) (3 pages). 2007, 2007	PRNEY, GRANT OF NEW E ADDRESS (INCLUDES Respectfully submitted By:	POWER OF ATTORNEY STATEMENT UNDER 3	
\18516\10\55237.1		<u> </u>	<u>. </u>	
CERTI	ficate of mailing or	TRANSMISSION (37 CF	TR 1.8(a))	
I hereby certify that or enclosed) is being:	this correspondence (alor	ng with any paper referre	ed to as being attached	
postage as fir	the United States Postal set class mail in an enfor Patents, P.O. Box 145	velope addressed to M	fail Stop Amendment,	
transmitted by	r facsimile on the date sice via facsimile at (571) 2	shown below to the Uni 73-8300.		

RECEIVED CENTRAL FAX CENTER

☑ 003/005

SEP 1 1 2007

Our Docket No.: 102959-202

Page 1 of 3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MATS HELLSTRÖM

Docket:

0208/76419-PCT-

U\$/RDK

ELISABET WALLGARD

MATTIAS KALÉN

Serial No.:

10/581,761

Art Unit:

Filed:

June 5, 2006

Examiner:

Assignee:

AngioGenetics Sweden AB

Conf. No.:

Customer No.:

27267

Our Reference

102959-202

Title:

ANGIOGENESIS AFFECTING POLYPEPTIDES, PROTEINS, AND

COMPOSITION, AND METHODS OF USE THEREOF

REVOCATION OF POWER OF ATTORNEY, GRANT OF NEW POWER OF ATTORNEY, AND CHANGE OF CORRESPONDENCE ADDRESS (INCLUDES STATEMENT UNDER 37 C.F.R. §3.73(b)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

AngioGenetics Sweden AB, of Stockholm, Sweden ("Assignee"), organized under the laws of Sweden, states that it is the current Assignee of the entire right, title, and interest to the above-identified U.S. patent application by virtue of a chain of title as follows:

_	CERTIFICATE OF MAILING OR TRANSMISSION (37 CFR 1.8(a))		
the second short this correspondence (along with any paper referred to as being attached or enclosed) is being:			
<u></u>	deposited with the United States Postal Service on the date shown below with sufficient postage as first class many deposited with the United States Postal Service on the date shown below with sufficient postage as first class many deposited with the United States Postal Service on the date shown below with sufficient postage as first class many deposited with the United States Postal Service on the date shown below with sufficient postage as first class many deposited with the United States Postal Service on the date shown below with sufficient postage as first class many deposited with the United States Postal Service on the date shown below with sufficient postage as first class many deposited with the United States Postal Service on the date shown below with sufficient postage as first class many deposited with the United States Postal Service on the date shown below with sufficient postage as first class many deposited with the United States Postal Service on the date shown below with sufficient postage as first class many deposited with the United States Postal Service on the date shown below with sufficient postage as first class many deposited with the United States Postal Service on the date shown below with sufficient postage as first class many deposited with the United States Postal Service on the date shown below with sufficient postage as first class many deposited with the United States Postal Service on the date shown below with sufficient postage as first class many deposited with the date shown below with the United States and the date shown below with sufficient postage as first class many deposited with the date shown below with the d		
ļ	The Control on the date shown below to the United States Patent and Trademark Office via facsimile at		
	(571) 273-8300. Date:		
1			

1.

Our Docket No.: 102959-202

Page 2 of 3

From: Mats Hellström Elisabet Wallgard Mattias Kalén

To: AngioGenetics Sweden AB

The document was recorded in the United States Patent and Trademark Office at Reel: 019168, Frame: 0474.

The undersigned is empowered to sign this statement on behalf of the Assignee.

Assignee hereby revokes all previous powers of attorney or authorization of agent given in this U.S. patent application.

Assignee hereby appoints the practitioners of Wiggin and Dana LLP, who are identified by the U.S. Patent & Trademark Office under Customer Number 27267 and to transact all business in the Patent and Trademark Office connected therewith.

Please address all future written and fax correspondence to Customer Number:

Patent Docket Coordinator WIGGIN and DANA LLP One Century Tower P.O. Box 1832 New Haven, CT 06508-1832 Telephone: (203) 498-4400 Facsimile: (203) 782-2889

Our Docket No.: 102959-202

Page 3 of 3

Please direct all phone and email communications to Todd E. Garabedian, Ph.D., Reg. No. 39,197 at Wiggin and Dana LLP, phone: 860-297-3716 and email: tgarabedian@wiggin.com.

Signature of authorized person for AngioGenetics Sweden AB

By: Mats Hellström

Title: Chief Executive Officer

Date: 23 August ____, 2007

\18516\10\55234.1